New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
15:35 EDTVRS, TRK, TFX, TFG, TAC, SXL, SA, PYA, PLP, PBYI, KMPR, HMN, GTY, CPK, CDI, BXG, BBXNYSE says cash equities market experienced issue with matching engine
The NYSE cash equities market has recovered from an issue with one matching engine affecting order processing and trade execution in 26 symbols. Recovery has been completed and all NYSE trading systems are functioning normally, the exchange stated. A list of affected symbols is available via the following link: Reference Link
News For BBX;BXG;CDI;CPK;GTY;HMN;KMPR;PBYI;PLP;PYA;SA;SXL;TAC;TFG;TFX;TRK;VRS From The Last 14 Days
Check below for free stories on BBX;BXG;CDI;CPK;GTY;HMN;KMPR;PBYI;PLP;PYA;SA;SXL;TAC;TFG;TFX;TRK;VRS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
12:17 EDTPBYIOn The Fly: Midday Wrap
Subscribe for More Information
11:08 EDTPBYIHigh option volume stocks
Subscribe for More Information
10:05 EDTPBYIPuma Biotechnology seen as takeover target after positive data
Subscribe for More Information
09:17 EDTPBYIOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTBBXBBX Capital Real Estate announces plans for Bonterra
Subscribe for More Information
07:48 EDTPBYIPuma Biotechnology price target raised to $300 from $144 at Leerink
Subscribe for More Information
07:47 EDTPBYIPuma Biotechnology price target raised to $325 from $125 at UBS
Subscribe for More Information
07:08 EDTTFXTeleflex signs new agreement with Amerinet
Subscribe for More Information
06:32 EDTPBYIPuma Biotechnology a likely acquisition target after data, says Citigroup
Citigroup raised its price target for Puma Biotechnology shares to $292 from $99 after the company announced positive Phase III data for its investigational breast cancer drug neratinib. Citi views Puma as a likely acquisition target saying the drug is likely to work in lung cancer and potentially other HER2mut cancers while the company has patent protection until 2030. The firm thinks Puma could be worth $291-$351 per share in a takeout scenario and keeps a Buy rating on the stock.
06:25 EDTPBYIPuma Biotechnology volatility is expected to move on positive top line results
Subscribe for More Information
July 22, 2014
18:33 EDTPBYIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Broadcom (BRCM), consensus up 3% after reporting second quarter results... Intuitive Surgical (ISRG), up 10.4%... Manhattan Associates (MANH), up 3%... Robert Half International (RHI), up 3.9%... Hawaiian Holdings (HA), up 3.1%... Microsoft (MSFT), up just under 1%... FMC Technologies (FTI), up 1.1%. ALSO HIGHER: Ballard Power Systems (BLDP), up 2.7% following purchase order from New Flyer Industries... Unwired Planet (UPIP), up 2.4% after filing a lawsuit against Microsoft for breach of contract. NOTABLE: Puma Biotechnology (PBYI), up 193.8% after reporting positive top line results from Phase III PB272 trial. DOWN AFTER EARNINGS: Xilinx (XLNX), down 8.7%... Apple (AAPL), down after reporting third quarter results and fourth quarter guidance... Juniper Networks (JNPR), down 4.7%... ALSO LOWER: Farmland Partners (FPI), down 3.8% after filing to sell 3.72M shares of common stock.
16:45 EDTPBYIPuma Biotechnology up 200% after positive top line PB272 trial results
Subscribe for More Information
16:27 EDTPBYIPuma Biotechnology reports positive top line results from Phase III PB272 trial
Subscribe for More Information
16:18 EDTPBYIPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
07:04 EDTTFXTeleflex granted FDA clearance for ARROW-Clark VectorFlow Catheter
Subscribe for More Information
July 21, 2014
09:04 EDTBBXBBX Capital acquires Helen Grace Chocolates
Subscribe for More Information
July 17, 2014
07:11 EDTVRSVerso Paper announces expiration of early tender time, withdrawal deadline
Verso Paper announced that as of 12:00 midnight, New York City time, at the end of Wednesday, July 16, the early tender time with respect to the previously announced exchange offers and consent solicitations by two of its wholly owned subsidiaries, Verso Paper Holdings and Verso Paper, with respect to their outstanding 8.75% Second Priority Senior Secured Notes due 2019 and 11 3/8% Senior Subordinated Notes due 2016 has expired and the deadline to withdraw tenders or revoke consents has passed. Holders of Old Second Lien Notes and Old Subordinated Notes may still participate in the exchange offers and consent solicitations through the final expiration time, which will be as of 12:00 midnight, New York City time, at the end of Wednesday, July 30, 2014, unless extended. As of 12:00 midnight, New York City time, at the end of Wednesday, July 16, the Issuers have been informed by the exchange agent that approximately $286.9M aggregate principal amount of the Old Second Lien Notes and approximately $17.7M aggregate principal amount of the Old Subordinated Notes had been tendered for exchange.
July 15, 2014
14:35 EDTPBYIPuma Biotechnology volatility elevated
Puma Biotechnology August call option implied volatility is at 138, September is at 113 December is at 95; compared to its 26-week average of 98 according to Track Data, suggesting large near term price movement.
July 9, 2014
05:53 EDTVRSStocks with implied volatility movement; VRS FTNT
Stocks with implied volatility movement; Verso Paper (VRS) 199, Fortinet (FTNT) 48 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use